Syndax Pharmaceuticalsの空売り状況は、投資家がSyndax Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Syndax Pharmaceuticals (NASDAQ:SNDX) 株価情報, 空売り情報

Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

JP Morgan released a survey on Thursday focused on the launch prospects of Syndax Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) Revuforj (revumenib) in relapsed/refractory (r/r) KMT2A acute leukemias and nucleophosmin 1 mutation acute <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">myeloid leukemia (NPM1 AML)</a>.
The FDA approved Revuforj in November 2024 as the first and only menin inhibitor for r/r acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42020752/syndax-announces-fda-approval-of-revuforj-revumenib-the-first-and-only-menin-inhibitor-to-treat-ad" rel="noreferrer noopener">one year and older</a>.
Revuforj generated $7.7 million in net product revenue during its first five weeks on the market.
The company expects to submit a supplemental application filing for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44073341/syndax-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">around year-end 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40396645/fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-" rel="noreferrer noopener">FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication</a>
JPMorgan says that, on average, surveyed physicians treated 8 KMT2A acute leukemia and 12 NPM1 AML patients.
Overall, surveyed physicians provided high ratings related to Revuforj&#8217;s clinical profile in both r/r KMT2A acute leukemias and NPM1 AML.
Analyst Anupam Rama writes that surveyed physicians indicated a high degree of comfort using Revuforj in r/r NPM1 should the product be incorporated into NCCN guidelines.
&#8220;In our view, survey results underscore that SNDX shares are currently materially undervalued on Revuforj in the r/r (KMT2A / NPM1) setting alone – which we value in the ~high-$20 to low-$30s / share range,&#8221; Rama writes.
For the near term, JPMorgan estimates 2025 Revuforj sales to be around $50 million (US only), largely driven by the KMT2A setting.
JPMorgan raised its price target from $39 to $41, accounting for a faster ramp to peak for Revuforj in both KMT2A acute leukemias and NPM1 AML, reiterating the Overweight rating.
Price Action: SNDX stock is up 0.43% at $14.16 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44432877/asia-markets-mixed-with-weak-china-europe-drops-dollar-strengthens-oil-slips-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">China, Hong Kong, And Europe Markets Dip; Dollar Strengthens &#8211; Global Markets Today While US Slept</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

News

Analyst Ratings

General

SNDX

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth

WIIM

Syndax Pharmaceuticals shares are trading higher after JP Morgan raised its price target on the stock from $39 to $41 and maintained an Overweight rating.

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $39 to $41.

Price Target

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $41

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $35 to $39.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and lowers the price target from $45 to $42.

Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $42

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Syndax Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimate.

For the first quarter of 2025, the Company expects research and development expenses to be&nbsp;$65 to $70 million&nbsp;and total research and development plus selling, general and administrative expenses to be&nbsp;$105 to $110 million. For the full year of 2025, the Company expects research and development expenses to be&nbsp;$260 to $280 million&nbsp;and total research and development plus selling, general and administrative expenses to be&nbsp;$415 to $435 million, which includes an estimated&nbsp;$45 million&nbsp;in non-cash stock compensation expense. The Company is not providing revenue guidance at this time.

Guidance

Syndax Sees Research & Development Expenses Of $65M-$70M In Q1, $260M-$280M In 2025

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.01) by 8.91 percent. This is a 10 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $7.68 million which missed the analyst consensus estimate of $85.91 million by 91.06 percent.

Earnings

Earnings Misses

Syndax Pharmaceuticals Q4 2024 GAAP EPS $(1.10) Misses $(1.01) Estimate, Sales $7.68M Miss $85.91M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report earnings for its second quarter. 
• TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $99.36 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $274.06 million. 
• Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $216.00 million. 
• Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $52.70 million. 
• Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) is projected to report quarterly loss at $0.16 per share on revenue of $7.64 million. 
• AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $17.01 million. 
• Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) is likely to report quarterly loss at $1.07 per share on revenue of $21.98 million. 
• Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $796.56 million. 
• Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) is projected to report quarterly loss at $0.22 per share on revenue of $16.89 million. 
• BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is expected to report quarterly loss at $0.03 per share on revenue of $22.77 million. 
• Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $828.01 million. 
• N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $113.77 million. 
• Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $55.44 million. 
• Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is likely to report quarterly loss at $0.35 per share on revenue of $25.62 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $6.42 million. 
• Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) is likely to report quarterly loss at $0.67 per share on revenue of $234.99 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is likely to report earnings for its fourth quarter. 
• Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $703.90 million. 
• California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $904.91 million. 
<h3>Companies Reporting After The Bell</h3>
• NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $1.07 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is likely to report earnings for its fourth quarter. 
• ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $113.40 million. 
• Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is expected to report quarterly loss at $0.08 per share on revenue of $5.30 million. 
• GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $288.33 million. 
• Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $65.90 million. 
• OFS Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFS#NASDAQ">OFS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $10.30 million. 
• Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) is likely to report earnings for its fourth quarter. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $334.82 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly loss at $0.25 per share on revenue of $130.04 million. 
• Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $95.23 million. 
• AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report quarterly loss at $0.15 per share on revenue of $1.88 million. 
• Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.60 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is projected to report quarterly loss at $0.46 per share on revenue of $159.91 million. 
• Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is likely to report quarterly loss at $0.08 per share on revenue of $270.50 million. 
• Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $82.56 million. 
• Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $83.91 million. 
• GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $206.48 million. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $334.82 million. 
• Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $19.83 million. 
• Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is likely to report quarterly loss at $0.05 per share on revenue of $53.44 million. 
• Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) is projected to report quarterly loss at $0.03 per share on revenue of $7.79 million. 
• Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $1.29 million. 
• NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $1.10 billion. 
• Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $263.33 million. 
• Concentra Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $463.65 million. 
• ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $70.65 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $669.10 million. 
• Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) is estimated to report earnings for its fourth quarter. 
• BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is expected to report quarterly loss at $0.05 per share on revenue of $106.20 million. 
• Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $38.39 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

ASTS

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BDSX

BLFS

BRCC

DAVE

EKSO

FTRE

GTLB

GUTS

HSII

JRVR

KBDC

MITT

MRSN

NABL

NATL

NOMD

NOVA

OCUL

OKTA

PLUG

RILY

RNGR

RPAY

SENS

SGRY

SPHR

STXS

TDUP

TGTX

Earnings Scheduled For March 3, 2025

The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
&nbsp;Niktimvo is the first and only FDA-approved prescription treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis.

INCY

Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February

Scotiabank analyst George Farmer maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Sector Perform and lowers the price target from $18 to $16.

Scotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Lowers Price Target to $16

– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64)&nbsp;show responses across all major subgroups, including heavily pretreated patients –
– 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort –
– 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML –
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –

Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj

<ul>
<li>82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –</li>
<li>64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –</li>
<li>Responses were rapid, durable and observed across all major subgroups in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –</li>
<li>Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting –</li>
</ul>

Reported Saturday, Syndax's Revuforj (revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $33 to $38.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $38

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $37 to $45.

Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $45

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham boosted the price target for Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from $290 to $375. Needham analyst John Todaro maintained a Buy rating. Coinbase shares closed at $305.85 on Friday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) from $49 to $51. HC Wainwright &amp; Co. analyst Edward White maintained a Buy rating. Syndax Pharmaceuticals shares closed at $15.83 on Friday. <a href="https://www.benzinga.com/quote/SNDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) price target from $160 to $153. Morgan Stanley analyst Stephen Grambling maintained an Equal-Weight rating. Hyatt shares settled at $152.94 on Friday. <a href="https://www.benzinga.com/quote/H/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) price target from $18 to $5. HC Wainwright &amp; Co. analyst Amit Dayal maintained a Buy rating. Plug Power shares closed at $1.87 on Friday. <a href="https://www.benzinga.com/quote/PLUG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted Bel Fuse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) price target from $79 to $95. Needham analyst James Ricchiuti maintained a Buy rating. Bel Fuse shares closed at $74.56 on Friday.  <a href="https://www.benzinga.com/quote/BELFB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) price target from $70 to $90. Baird analyst Vikram Kesavabhotla upgraded the stock from Neutral to Outperform. Roku shares closed at $68.87 on Friday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $305 to $330. Baird analyst Joe Vruwink maintained an Outperform rating. Autodesk shares settled at $299.15 on Friday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted MBIA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) price target from $6.5 to $9. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith upgraded the stock from Market Perform to Outperform. MBIA shares closed at $6.03 on Friday. <a href="https://www.benzinga.com/quote/MBI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) from $10 to $6. B of A Securities analyst Tazeen Ahmad maintained a Neutral rating. PepGen shares closed at $4.12 on Friday. <a href="https://www.benzinga.com/quote/PEPG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted Assured Guaranty Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) price target from $92 to $105. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintained an Outperform rating. Assured Guaranty shares closed at $91.02 on Friday. <a href="https://www.benzinga.com/quote/AGO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying ROKU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="561" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-1024x561.png" alt="" class="wp-image-652910" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-1024x561.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18082358/image-184.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ADSK

BELFB

COIN

PEPG

ROKU

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright &amp; Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and raises the price target from $49 to $51.

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $51

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

Press Releases

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Announces Participation in February Investor Conferences

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Legal

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Syndax Announces Participation in March Investor Conferences

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Comments

Syndax Pharmaceuticals

空売り

Syndax Pharmaceuticals (NASDAQ:SNDX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル